A study to evaluate the effectiveness and safety of JNJ-88545223 in people with active psoriatic arthritis

2 1

What is this study about?

This study aims to evaluate the effectiveness and safety of the drug JNJ-88545223 for people living with Psoriatic Arthritis. Psoriatic Arthritis is a type of inflammatory disease that causes joint pain, swelling, and stiffness, often occurring in people who also have psoriasis, a skin condition characterized by red, itchy patches.

Participants in this research will receive different doses of the tablet form of JNJ-88545223 or a placebo. The study is randomized, meaning participants are assigned to a specific group by chance, and double-blind, which means neither the participants nor the researchers know which treatment is being given. This process is used to ensure the results are as objective as possible.

Who Can Join the Study?

You must be 18 years of age or older.
You must have been diagnosed with psoriatic arthritis (a type of arthritis that affects people who also have psoriasis) for at least 3 months.
You must meet specific medical standards for psoriatic arthritis during the initial check-up.
You must have active disease, which is defined as having at least 3 swollen joints and 3 painful joints during the screening and at the start of the study.
You must have a high enough level of CRP, which is a blood marker that shows there is inflammation in your body.
You must have active plaque psoriasis, which means having at least one skin patch that is at least 2 cm wide, or having nail changes caused by psoriasis.
Your disease must still be active even though you have used or are currently using at least one of the following types of medicine: conventional DMARDs (medicines that help slow down the disease), apremilast, or anti-TNF agents (a specific type of biological medicine).
If you are taking conventional DMARDs, you must have taken them for at least 12 weeks, or you must have been unable to take them due to intolerance (meaning the medicine caused bad side effects).
If you are using anti-TNF agents, you must have either not had a good response to the medicine after 12 to 14 weeks, or you must have stopped taking them because of safety or tolerability issues.
If you are currently taking conventional DMARDs, your dose must have been stable (not changed) for at least 4 weeks, and you must not have any serious toxic side effects from the medicine.
If you are not currently taking certain DMARDs, you must have stopped taking them for at least 4 weeks (for some) or 12 weeks (for others) before starting the study.
Specific dose limits must be met for medicines like methotrexate, sulfasalazine, hydroxychloroquine, and leflunomide.
If you are taking apremilast, you must be on a stable dose for at least 12 weeks before the study begins.
If you are not taking apremilast, you must have stopped taking it at least 4 weeks before the study starts.
If you use NSAIDs (pain relievers like ibuprofen) or other analgesics (painkillers) for your arthritis, you must have been on a stable dose for at least 2 weeks, or have been off them for at least 2 weeks.
If you use oral corticosteroids (steroid pills used to reduce inflammation), you must be on a stable dose for at least 2 weeks, or have been off them for at least 2 weeks.

Who Cannot Join the Study?

You have a history of or are currently showing signs of serious, worsening, or poorly managed problems with your kidneys (renal), liver (hepatic), heart (cardiac), blood vessels (vascular), lungs (pulmonary), digestive system (gastrointestinal), hormone system (endocrine), nervous system (neurologic), blood (hematologic), joints and bones (rheumatologic), mental health (psychiatric), urinary or reproductive system (genitourinary), or chemical processes in the body (metabolic).
You currently have cancer (malignancy) or have had cancer within the last 5 years, unless it was a specific type of skin cancer or a specific type of early-stage cervical cancer that has been fully treated and has not returned for at least 12 weeks.
You have other diseases that cause swelling or redness in the body (inflammatory diseases) that could make it difficult to see if the study medication is actually working.
Your blood tests show levels of rheumatoid factor or anti-CCP antibodies (specific proteins in the blood often linked to certain types of arthritis) that are higher than the upper limit of normal (ULN), which is the highest level considered healthy by a laboratory.
You have an active infection of the liver (hepatitis) caused by a virus or other germ.
You have a history of long-lasting or repeating infections (chronic or recurrent infectious disease).

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
CENTRUM MEDYCZNE REUMA PARK	Warsaw	Poland
Vasarhelyi Sarkanyfu Kft.	Hodmezovasarhely	Hungary
Futuremeds Sp. z o.o.	Wroclaw	Poland
Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik	Bialystok	Poland

Other Sites

Site Name	City	Country
Bekes Varmegyei Koezponti Korhaz	Gyula	Hungary
Qualiclinic Kft.	Budapest	Hungary
Malopolskie Badania Kliniczne Sp. z o.o.	Cracow	Poland
MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH	Hamburg	Germany
L.K.N. Arthrocentrum s.r.o.	Hlucin	Czechia
Centrum für Angewandte Immunologie & Rheumatologie (CAIR)	Heidelberg	Germany
Rheumatologische Schwerpunktpraxis	Berlin	Germany
Complex Rendelo Med Zrt.	Szekesfehervar	Hungary
Accellacare Espana S.L.	Alcobendas	Spain
Rheuma Medicus Sp. z o.o.	Warsaw	Poland
Etyka Osrodek Badan Klinicznych Tomasz Pesta S.K.A.	Olsztyn	Poland
Obudai Egeszseguegyi Centrum Kft.	Dunaújváros	Hungary
Szpital Uniwersytecki Nr 2 Im Dr Jana Biziela W Bydgoszczy	Bydgoszcz	Poland
Clintrial s.r.o.	Prague	Czechia
Pratia Pardubice a.s.	Pardubice	Czechia
Virgen del Rocío University Hospital	Sevilla	Spain
Charite Universitaetsmedizin Berlin KöR	Berlin	Germany
Semmelweis University	Budapest	Hungary
Universidade De Santiago De Compostela	Santiago De Compostela	Spain
Pratia S.A.	Skorzewo	Poland
Medical Plus s.r.o.	Uherske Hradiste	Czechia
NZOZ Lecznica Mak Med s.c.	Nadarzyn	Poland
Vital-Medicina Kft.	Veszprem	Hungary
Hautarztpraxis Mortazawi GbR	Remscheid	Germany
Centrum Kliniczno-Badawcze J.Brzezicki B.Gornikiewicz-Brzezicka Lekarze sp.p.	Elblag	Poland
Mgxuavvzm Ijztftgolr Cjcxival Scswafxw Smn z oied	Warsaw	Poland
Tsmkrddacvh uzu Smwhynuderi Bwreijbn Geco	Bad Bentheim	Germany
Rkejwyc phb siupkm	Karvina	Czechia
Rectvw sxiaoh	Breclav	Czechia
Ryfiacirnhteocs Labynxvt Zdyfznb fxg kldlbfqcz Sqriqkc	Cottbus	Germany
Elq Lpxzzk	Lublin	Poland
Hifbethdwlwjpn Dq Mqu Mockzsku Hvmksync	Witten	Germany
Dogrpbgjgwxv Qhttx	Mainz	Germany
Hlleldqr Unyngldzrvayf dd A Cykiuj	A Coruna Galicia	Spain

Trial status

Country	Status	Recruitment Start
Czechia	Recruiting	30.03.2026
Germany	Recruiting	30.03.2026
Hungary	Recruiting	30.03.2026
Poland	Recruiting	30.03.2026
Spain	Recruiting	30.03.2026

Trial locations

JNJ-88545223 is an experimental medication taken by mouth in tablet form. It is being studied to see how well it works and how safe it is for people who have active psoriatic arthritis.

Psoriatic Arthritis – This is a type of inflammatory arthritis that affects some people who have psoriasis, a skin condition. The disease causes inflammation in the joints, which can lead to swelling and pain. It may also affect the skin, nails, and other parts of the body. Over time, the inflammation can cause damage to the joints and change their shape. The condition often moves through periods of activity and periods of relative calm.

Trial ID:

2025-523141-10-00

Protocol code:

88545223PSA2001

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

A study to evaluate the effectiveness and safety of JNJ-88545223 in people with active psoriatic arthritis

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?